Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate use of Remimazolam for the use of sedation of five intensive care unit (ICU) patients with COVID19

Next Previous
Search
Trial Profile

Compassionate use of Remimazolam for the use of sedation of five intensive care unit (ICU) patients with COVID19

Status: Not yet recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remimazolam (Primary)
  • Indications Sedation
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 12 Aug 2020 According to a PAION media release, with currently significantly fewer COVID-19 patients on the ICU, an extension to additional patients is not planned for now.
    • 09 Jun 2020 New trial record
    • 02 Jun 2020 According to a PAION media release, the local Ethics Commitee of the Hospital San Raffaele in Milan/Italy has granted approval for the compassionate use of remimazolam for the use of sedation of five intensive care unit (ICU) patients with COVID19 and treatment might be extended to a wider number of patients at the hospital.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top